Chicago Partners Investment Group LLC Sells 1,654 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Key Points

• Chicago Partners Investment Group LLC reduced its holdings in Ascendis Pharma A/S by 31.7%, now owning 3,571 shares valued at approximately $575,000.
• Major investors like JPMorgan Chase & Co. increased their stake in Ascendis Pharma by 94.4%, now holding 77,427 shares valued at about $10.7 million.
• Analysts have shown increased optimism, with Evercore ISI raising its price target for the stock to $280 and a majority of analysts rating it as a "buy."

Chicago Partners Investment Group LLC decreased its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 31.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,571 shares of the biotechnology company's stock after selling 1,654 shares during the period. Chicago Partners Investment Group LLC's holdings in Ascendis Pharma A/S were worth $575,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its stake in Ascendis Pharma A/S by 94.4% during the fourth quarter. JPMorgan Chase & Co. now owns 77,427 shares of the biotechnology company's stock valued at $10,659,000 after buying an additional 37,593 shares during the period. Pursue Wealth Partners LLC bought a new stake in Ascendis Pharma A/S during the first quarter worth about $226,000. Geode Capital Management LLC lifted its stake in Ascendis Pharma A/S by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 57,077 shares of the biotechnology company's stock worth $7,858,000 after purchasing an additional 629 shares during the last quarter. Sigma Planning Corp bought a new stake in Ascendis Pharma A/S during the first quarter worth about $236,000. Finally, Diversify Advisory Services LLC bought a new stake in Ascendis Pharma A/S during the first quarter worth about $332,000.

Analyst Ratings Changes

ASND has been the subject of several research analyst reports. Evercore ISI lifted their price target on Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. Stifel Nicolaus lifted their price target on Ascendis Pharma A/S from $212.00 to $254.00 and gave the stock a "buy" rating in a research note on Friday. Oppenheimer reaffirmed an "outperform" rating and set a $224.00 price target (up previously from $215.00) on shares of Ascendis Pharma A/S in a research note on Friday, June 13th. Wall Street Zen raised Ascendis Pharma A/S from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, Citigroup lifted their price target on Ascendis Pharma A/S from $243.00 to $290.00 and gave the stock a "buy" rating in a research note on Friday. Sixteen equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $239.80.

Ascendis Pharma A/S Price Performance

ASND opened at $191.49 on Friday. The business has a 50 day simple moving average of $174.03 and a two-hundred day simple moving average of $159.06. The firm has a market capitalization of $11.71 billion, a price-to-earnings ratio of -37.11 and a beta of 0.41. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $199.99.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) EPS for the quarter, beating analysts' consensus estimates of ($1.42) by $0.49. The business had revenue of $216.28 million for the quarter, compared to the consensus estimate of $163.17 million. As a group, sell-side analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.